First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations.-论文-万方医学网

第一作者： Tomohito,Kuwako

第一单位： Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, 3-39-15, Showa-machi, Maebashi, Gunma, 371-8511, Japan.

作者： Tomohito,Kuwako ^[1] ; Hisao,Imai ^[2] ; Tomomi,Masuda ^[1] ; Yosuke,Miura ^[3] ; Kaori,Seki ^[1] ; Reiko,Yoshino ^[4] ; Kyoichi,Kaira ^[5] ; Mitsuyoshi,Utsugi ^[6] ; Kimihiro,Shimizu ^[7] ; Noriaki,Sunaga ^[1] ; Yoshio,Tomizawa ^[4] ; Shinichi,Ishihara ^[8] ; Takao,Ishizuka ^[9] ; Akira,Mogi ^[10] ; Takeshi,Hisada ^[1] ; Koichi,Minato ^[3] ; Atsushi,Takise ^[11] ; Ryusei,Saito ^[4] ; Masanobu,Yamada ^[1]

作者单位： Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, 3-39-15, Showa-machi, Maebashi, Gunma, 371-8511, Japan. ^[1] Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, 3-39-15, Showa-machi, Maebashi, Gunma, 371-8511, Japan. m06701014@gunma-u.ac.jp. ^[2] Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Ohta, Gunma, Japan. ^[3] Division of Respiratory Medicine, National Hospital Organization Nishigunma Hospital, Shibukawa, Gunma, Japan. ^[4] Department of Oncology Clinical Development, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan. ^[5] Division of Internal Medicine, Kiryu Kosei General Hospital, Kiryu, Gunma, Japan. ^[6] Department of Thoracic Visceral Organ Surgery, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan. ^[7] Division of Internal Medicine, Isesaki Municipal Hospital, Isesaki, Gunma, Japan. ^[8] Division of Internal Medicine, Public Tomioka General Hospital, Tomioka, Gunma, Japan. ^[9] Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan. ^[10] Division of Respiratory Medicine, Maebashi Red Cross Hospital, Maebashi, Gunma, Japan. ^[11]

主题词老年人(Aged);老年人, 80以上(Aged, 80 and over);衰老(Aging);抗肿瘤药(Antineoplastic Agents);癌, 非小细胞肺(Carcinoma, Non-Small-Cell Lung);药疹(Drug Eruptions);药物监测(Drug Monitoring);可行性研究(Feasibility Studies);女(雌)性(Female);随访研究(Follow-Up Studies);人类(Humans);发病率(Incidence);日本(Japan);肺肿瘤(Lung Neoplasms);男(雄)性(Male);突变(Mutation);蛋白激酶抑制剂(Protein Kinase Inhibitors);喹唑啉类(Quinazolines);回顾性研究(Retrospective Studies);疾病严重程度指数(Severity of Illness Index);存活率分析(Survival Analysis)

DOI 10.1007/s00280-015-2841-5

PMID 26254024

发布时间 2018-12-02

检索历史清除

First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations.

Cancer chemotherapy and pharmacology

相似文献

Cancer chemotherapy and pharmacology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations.

Cancer chemotherapy and pharmacology

相似文献

Cancer chemotherapy and pharmacology

相关期刊

检索历史清除